Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
28.53
-0.71 (-2.43%)
At close: Aug 6, 2025, 4:00 PM
29.10
+0.57 (2.00%)
After-hours: Aug 6, 2025, 5:58 PM EDT

Company Description

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors.

It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing’s disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors.

In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves’ disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity.

The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist.

Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals logo
CountryUnited States
Founded2008
IPO DateJul 18, 2018
IndustryBiotechnology
SectorHealthcare
Employees437
CEOR. Struthers

Contact Details

Address:
6055 Lusk Boulevard
San Diego, California 92121
United States
Phone858 450 6464
Websitecrinetics.com

Stock Details

Ticker SymbolCRNX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001658247
CUSIP Number22663K107
ISIN NumberUS22663K1079
Employer ID26-3744114
SIC Code2834

Key Executives

NamePosition
Dr. R. Scott Struthers Ph.D.Founder, President, Chief Executive Officer and Director
Dr. Stephen F. Betz Ph.D.Co-Founder and Chief Scientific Officer
Jeff E. KnightChief Operating Officer
Dr. Dana Pizzuti M.D.Chief Medical and Development Officer
Tobin C. SchilkeChief Financial Officer
Gayathri DiwakarHead of Investor Relations
Garlan AdamsChief Legal Officer and Corporate Secretary
Adriana Cabre M.B.A.Chief Human Resources Officer
Dr. Alan S. Krasner M.D.Chief Endocrinologist
Kevin CappsHead of Intellectual Property

Latest SEC Filings

DateTypeTitle
Jun 30, 20258-KCurrent Report
Jun 26, 20258-KCurrent Report
Jun 12, 20258-KCurrent Report
Jun 12, 2025144Filing
May 20, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
May 12, 2025SCHEDULE 13G/AFiling
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
Apr 23, 2025ARSFiling
Apr 23, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material